At the news
? BEARISHIMPACT 7/10 425 filed Jun 24, 2026 at 17:10 ET
Passage Bio announced a definitive all-stock merger with Remix Therapeutics, where pre-merger Passage shareholders will own only ~7% of the combined company, while Remix shareholders (including PIPE investors) will own ~93%. The deal is supported by an oversubscribed $100M+ private placement led by Decheng Capital, funding the combined entity into 2028 to advance Remix's lead program REM-422, an oral MYB mRNA degrader showing a 43% ORR in adenoid cystic carcinoma. Passage shareholders also receive contingent value rights tied to legacy gene therapy milestones.
- Pre-merger Passage Bio shareholders expected to own approximately 7% of the combined company at closing.
- Pre-merger Remix shareholders, including PIPE participants, expected to own approximately 93%.
- Concurrent oversubscribed private placement led by Decheng Capital with total gross proceeds of over $100M.
- Combined company expected to have cash runway into 2028.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access